Mainz Biomed N.V (NASDAQ: MYNZ)’s stock price has dropped by -7.72 in relation to previous closing price of 4.73. Nevertheless, the company has seen a loss of -22.19% in its stock price over the last five trading days. globenewswire.com reported 2025-03-13 that Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement for the Portfolio of mRNA Biomarkers, with Continued Development of Machine Learning AI-Based Algorithm Based on Liquid Biosciences EMERGE Platform BERKELEY, Calif. and MAINZ, Germany, March 13, 2025 (GLOBE NEWSWIRE) — Mainz Biomed N.V.
Is It Worth Investing in Mainz Biomed N.V (NASDAQ: MYNZ) Right Now?
Moreover, the 36-month beta value for MYNZ is 0.33. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for MYNZ is 2.11M and currently, short sellers hold a 3.78% of that float. On March 17, 2025, MYNZ’s average trading volume was 223.14K shares.
MYNZ’s Market Performance
The stock of Mainz Biomed N.V (MYNZ) has seen a -22.19% decrease in the past week, with a -42.41% drop in the past month, and a -27.25% fall in the past quarter. The volatility ratio for the week is 15.03%, and the volatility levels for the past 30 days are at 14.35% for MYNZ. The simple moving average for the last 20 days is -17.99% for MYNZ’s stock, with a simple moving average of -62.01% for the last 200 days.
Analysts’ Opinion of MYNZ
Many brokerage firms have already submitted their reports for MYNZ stocks, with Maxim Group repeating the rating for MYNZ by listing it as a “Buy.” The predicted price for MYNZ in the upcoming period, according to Maxim Group is $14 based on the research report published on February 14, 2025 of the current year 2025.
MYNZ Trading at -19.68% from the 50-Day Moving Average
After a stumble in the market that brought MYNZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.34% of loss for the given period.
Volatility was left at 14.35%, however, over the last 30 days, the volatility rate increased by 15.03%, as shares sank -33.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.28% lower at present.
During the last 5 trading sessions, MYNZ fell by -22.19%, which changed the moving average for the period of 200-days by -80.91% in comparison to the 20-day moving average, which settled at $5.32. In addition, Mainz Biomed N.V saw 1.04% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MYNZ
Current profitability levels for the company are sitting at:
- -29.75 for the present operating margin
- 0.57 for the gross margin
The net margin for Mainz Biomed N.V stands at -29.36. The total capital return value is set at -4.32.
Based on Mainz Biomed N.V (MYNZ), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at -2.96. The debt to equity ratio resting at 2.28. The interest coverage ratio of the stock is -32.91.
Currently, EBITDA for the company is -25.01 million with net debt to EBITDA at -0.01. When we switch over and look at the enterprise to sales, we see a ratio of 11.22. The receivables turnover for the company is 2.53for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
To wrap up, the performance of Mainz Biomed N.V (MYNZ) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
